CA3020179C - Formulations d'oxytocine contenant du magnesium et procedes d'utilisation - Google Patents

Formulations d'oxytocine contenant du magnesium et procedes d'utilisation

Info

Publication number
CA3020179C
CA3020179C CA3020179A CA3020179A CA3020179C CA 3020179 C CA3020179 C CA 3020179C CA 3020179 A CA3020179 A CA 3020179A CA 3020179 A CA3020179 A CA 3020179A CA 3020179 C CA3020179 C CA 3020179C
Authority
CA
Canada
Prior art keywords
magnesium
oxytocin peptide
oxytocin
disorder
magnesium ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3020179A
Other languages
English (en)
Other versions
CA3020179A1 (fr
Inventor
Dean Carson
David C. Yeomans
Original Assignee
Tonix Pharma Ltd Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd Ireland filed Critical Tonix Pharma Ltd Ireland
Priority claimed from PCT/US2017/027265 external-priority patent/WO2017180781A1/fr
Publication of CA3020179A1 publication Critical patent/CA3020179A1/fr
Application granted granted Critical
Publication of CA3020179C publication Critical patent/CA3020179C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des procédés et des compositions pour le traitement de troubles du spectre de l'autisme, de troubles associés et de symptômes desdits troubles, comprenant la co-administration d'un peptide d'oxytocine et d'ions de magnésium. La co-administration d'un peptide d'oxytocine et d'ions magnésium entraîne un effet synergique ou amélioré sur la réduction des déficits sociaux et de communication chez un patient souffrant d'un trouble du spectre de l'autisme.
CA3020179A 2016-04-12 2017-04-12 Formulations d'oxytocine contenant du magnesium et procedes d'utilisation Active CA3020179C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321654P 2016-04-12 2016-04-12
US62/321,654 2016-04-12
PCT/US2017/027265 WO2017180781A1 (fr) 2016-04-12 2017-04-12 Formulations d'oxytocine contenant du magnésium et procédés d'utilisation

Publications (2)

Publication Number Publication Date
CA3020179A1 CA3020179A1 (fr) 2017-10-19
CA3020179C true CA3020179C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
AU2020286221B2 (en) Magnesium-containing oxytocin formulations and methods of use
US20250319153A1 (en) Magnesium-containing oxytocin formulations and methods of use
HK40090944A (en) Magnesium-containing oxytocin formulations and methods of use
HK40108141A (en) Magnesium-containing oxytocin formulations and methods of use
HK40005263B (en) Magnesium-containing oxytocin formulations and methods of use
HK40005263A (en) Magnesium-containing oxytocin formulations and methods of use
BR112017014545B1 (pt) Formulações de oxitocina que contém magnésio e métodos de uso
HK1252942B (en) Magnesium-containing oxytocin formulations and methods of use